Ironwood Financial Statements From 2010 to 2024

IRWD Stock  USD 3.67  0.15  4.26%   
Ironwood Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Ironwood Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Ironwood Pharmaceuticals financial statements helps investors assess Ironwood Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Ironwood Pharmaceuticals' valuation are summarized below:
Gross Profit
366.3 M
Profit Margin
(0.01)
Market Capitalization
587.3 M
Enterprise Value Revenue
2.8803
Revenue
378.4 M
There are over one hundred nineteen available fundamental trends for Ironwood Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Ironwood Pharmaceuticals' regular performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 2.1 B. The current year's Enterprise Value is expected to grow to about 2.4 B

Ironwood Pharmaceuticals Total Revenue

231.75 Million

Check Ironwood Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ironwood Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 19.9 M or Total Revenue of 231.7 M, as well as many indicators such as Price To Sales Ratio of 3.82, Dividend Yield of 0.0 or Days Sales Outstanding of 142. Ironwood financial statements analysis is a perfect complement when working with Ironwood Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Ironwood Pharmaceuticals Correlation against competitors.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

Ironwood Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets499.5 M471.1 M507.6 M
Slightly volatile
Short and Long Term Debt Total751.3 M715.5 M344.8 M
Slightly volatile
Other Current Liabilities67.6 M64.3 M20.6 M
Slightly volatile
Total Current Liabilities289.9 M276.1 M95.4 M
Slightly volatile
Other Liabilities8.3 M8.8 M45.9 M
Slightly volatile
Property Plant And Equipment Net19.6 M18.2 M23.7 M
Pretty Stable
Current Deferred Revenue1.1 M1.1 M10.4 M
Pretty Stable
Accounts Payable7.4 M7.8 M25.6 M
Slightly volatile
Cash87.5 M92.2 M203.1 M
Slightly volatile
Non Current Assets Total143 M237.8 M149.8 M
Slightly volatile
Non Currrent Assets Other3.4 M3.6 M40.6 M
Very volatile
Other Assets0.951.083.1 M
Slightly volatile
Long Term Debt252.1 M498.3 M276.3 M
Slightly volatile
Cash And Short Term Investments87.5 M92.2 M267 M
Slightly volatile
Net Receivables135.6 M129.1 M71.5 M
Slightly volatile
Common Stock Total Equity125.3 K177.1 K134.1 K
Slightly volatile
Common Stock Shares Outstanding137.1 M155.4 M138.9 M
Slightly volatile
Liabilities And Stockholders Equity499.5 M471.1 M507.6 M
Slightly volatile
Non Current Liabilities Total370.6 M541.3 M352.3 M
Slightly volatile
Other Current Assets17.8 M12 M9.1 M
Slightly volatile
Other Stockholder EquityB1.4 B1.1 B
Slightly volatile
Total Liabilities454.8 M817.4 M434 M
Slightly volatile
Property Plant And Equipment Gross20.1 M27.1 M24.3 M
Pretty Stable
Total Current Assets356.5 M233.3 M357.8 M
Slightly volatile
Short Term Debt212.8 M202.7 M43.3 M
Slightly volatile
Common Stock128.1 K156 K132.9 K
Slightly volatile
Property Plant Equipment5.4 M5.7 M18.7 M
Slightly volatile
Long Term Debt Total311.5 M455.7 M277.7 M
Slightly volatile
Capital Surpluse1.3 B1.6 B1.2 B
Slightly volatile
Capital Lease Obligations9.9 M17.7 M8.5 M
Slightly volatile
Deferred Long Term Liabilities13.2 M13.9 M37.3 M
Pretty Stable
Non Current Liabilities Other29.8 M28.4 M13.9 M
Pretty Stable
Short and Long Term Debt184.4 M229.5 M124.4 M
Slightly volatile
Long Term Investments12.5 M13.1 M64.3 M
Slightly volatile
Net Invested Capital413.7 M351.6 M392.5 M
Very volatile
Capital Stock126 K156 K153.5 K
Pretty Stable

Ironwood Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.5 M1.6 M5.6 M
Slightly volatile
Interest Expense19.9 M21.6 M21.8 M
Slightly volatile
Total Revenue231.7 M442.7 M247.4 M
Slightly volatile
Gross Profit224 M441.2 M238.9 M
Slightly volatile
Other Operating Expenses243.2 M233.7 M247.4 M
Pretty Stable
Research Development108.7 M116.1 M104.4 M
Very volatile
Cost Of Revenue1.5 M1.6 M20.6 M
Slightly volatile
Total Operating Expenses235.7 M232.1 M239.1 M
Pretty Stable
Selling General Administrative138.7 M148 M133.6 M
Slightly volatile
Non Recurring16.8 M17.7 M24.8 M
Very volatile
Interest Income24.4 M23.2 M20.8 M
Slightly volatile
Reconciled Depreciation1.3 M1.4 M9.7 M
Slightly volatile

Ironwood Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation23.8 M32 M25.1 M
Slightly volatile
Begin Period Cash Flow690.8 M657.9 M240.5 M
Slightly volatile
Depreciation1.5 M1.6 M7.6 M
Slightly volatile
Capital Expenditures259.4 K273 K11.4 M
Pretty Stable
End Period Cash Flow87.5 M92.2 M204.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.824.016311.8551
Slightly volatile
Days Sales Outstanding142106143
Slightly volatile
Stock Based Compensation To Revenue0.06870.07230.1697
Slightly volatile
Capex To Depreciation0.160.17331.1829
Pretty Stable
EV To Sales5.155.424412.1336
Slightly volatile
Inventory Turnover0.971.027.6687
Pretty Stable
Days Of Inventory On Hand560370720
Slightly volatile
Payables Turnover0.190.20111.4023
Slightly volatile
Sales General And Administrative To Revenue1.380.81.1215
Pretty Stable
Average Inventory379.6 K562.5 K383.7 K
Slightly volatile
Research And Ddevelopement To Revenue0.250.26221.1226
Slightly volatile
Capex To Revenue6.0E-46.0E-40.0953
Slightly volatile
Cash Per Share0.560.59292.6747
Slightly volatile
Days Payables Outstanding1.7 K1.8 K19.6 K
Pretty Stable
Current Ratio0.80.84496.4955
Pretty Stable
Receivables Turnover3.263.428816.5433
Slightly volatile
Graham Number21.1217.978411.158
Pretty Stable
Capex Per Share0.00170.00180.107
Slightly volatile
Revenue Per Share1.582.84841.7566
Slightly volatile
Interest Debt Per Share4.864.62892.413
Slightly volatile
Debt To Assets1.561.48140.6583
Slightly volatile
Operating Cycle101106724
Slightly volatile
Days Of Payables Outstanding1.7 K1.8 K19.6 K
Pretty Stable
Quick Ratio0.80.84496.4396
Pretty Stable
Cash Ratio0.320.33384.1299
Slightly volatile
Days Of Inventory Outstanding560370720
Slightly volatile
Days Of Sales Outstanding142106143
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.520.99851.3276
Very volatile
Fixed Asset Turnover25.5824.364912.4754
Slightly volatile
Debt Ratio1.561.48140.6583
Slightly volatile
Price Sales Ratio3.824.016311.8551
Slightly volatile
Asset Turnover0.990.93980.5301
Slightly volatile
Gross Profit Margin0.740.99640.922
Very volatile

Ironwood Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.1 BB1.9 B
Slightly volatile
Enterprise Value2.4 B2.2 BB
Slightly volatile

Ironwood Fundamental Market Drivers

Forward Price Earnings12.3305
Cash And Short Term Investments92.2 M

Ironwood Upcoming Events

15th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Ironwood Pharmaceuticals Financial Statements

Ironwood Pharmaceuticals stakeholders use historical fundamental indicators, such as Ironwood Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Ironwood Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ironwood Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Ironwood Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ironwood Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.1 M1.1 M
Total Revenue442.7 M231.7 M
Cost Of Revenue1.6 M1.5 M
Stock Based Compensation To Revenue 0.07  0.07 
Sales General And Administrative To Revenue 0.80  1.38 
Research And Ddevelopement To Revenue 0.26  0.25 
Revenue Per Share 2.85  1.58 
Ebit Per Revenue 0.47  0.50 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:
Check out the analysis of Ironwood Pharmaceuticals Correlation against competitors.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Earnings Share
(0.01)
Revenue Per Share
2.393
Quarterly Revenue Growth
(0.20)
Return On Assets
0.1305
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.